TY - JOUR
T1 - Factors at admission associated with bleeding risk in medical patients
T2 - Findings from the improve investigators
AU - Decousus, Hervé
AU - Tapson, Victor F.
AU - Bergmann, Jean François
AU - Chong, Beng H.
AU - Froehlich, James B.
AU - Kakkar, Ajay K.
AU - Merli, Geno J.
AU - Monreal, Manuel
AU - Nakamura, Mashio
AU - Pavanello, Ricardo
AU - Pini, Mario
AU - Piovella, Franco
AU - Spencer, Frederick A.
AU - Spyropoulos, Alex C.
AU - Turpie, Alexander G.G.
AU - Zotz, Rainer B.
AU - FitzGerald, Gordon
AU - Anderson, Frederick A.
N1 - Funding Information:
Funding/Support: The IMPROVE study was supported by an unrestricted educational grant from Sanofi-Aventis to the Center for Outcomes Research at the University of Massachusetts Medical School.
Funding Information:
Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Anderson has received research support from Sanofi-Aventis, The Medicines Company, Procter & Gamble, and Scios; has been a consultant for Sanofi-Aventis, GlaxoSmithKline, Millennium, and Sage; and has served on advisory boards for Sanofi-Aventis and The Medicines Company. Dr Bergmann has received honoraria from Sanofi-Aventis and AstraZeneca. Dr Chong has served on advisory boards for Bayer, Boehringer-Ingelheim, and GlaxoSmithKline, and has been a speaker for Bayer. Dr Decousus has received research support from Sanofi-Aventis, GlaxoSmithKline, and Bayer. Dr Froehlich has received research support from Blue Cross Blue Shield of Michigan, Gore, and the Mardigian Foundation; has been a consultant for Pfizer and Sanofi-Aventis; and has received honoraria from Pfizer, Sanofi-Aventis, and Merck/Schering-Plough. Dr Kakkar has received research funding and has served on advisory boards for Bayer HealthCare, Sanofi-Aventis, Boehringer-Ingelheim, Pfizer, Bristol-Meyers Squibb, and Eisai; has been a consultant for Bayer HealthCare, Sanofi-Aventis, Boehringer-Ingelheim, Pfizer, Bristol-Meyers Squibb, Eisai, Aryx Therapeutics, and Canyon; and has received honoraria from Bayer HealthCare, Sanofi-Aventis, Boehringer-Ingelheim, Pfizer, Bristol-Meyers Squibb, Eisai, and GlaxoSmithKline. Dr Merli has received research support from and served on the advisory boards of Sanofi-Aventis Bristol-Meyers Squibb, and Bayer; and has been a speaker for Sanofi-Aventis. Dr Nakamura has been a consultant for Daiichi-Sankyo, GlaxoSmithKline, and Astellas. Dr Pavanello has received research support from Sanofi-Aventis; has served on an advisory board for Bayer; and has been a speaker for Bayer, Pfizer, and Novartis. Dr Piovella has received research support from GlaxoSmithKline; has served on advisory boards for Bayer, Boehringer-Ingelheim, and GlaxoSmithKline; and has been a speaker for Bayer, Boehringer-Ingelheim, GlaxoSmithKline, and Sanofi-Aventis. Dr Pini has received honoraria from Sanofi-Aventis. Dr Spencer has been a consultant for and has received grants from Sanofi-Aventis. Dr Spyropoulos has been a consultant for Sanofi-Aventis. Dr Tapson has received research support from, and has been a consultant for, Sanofi-Aventis. Dr Turpie has served on advisory boards for Sanofi-Aventis, Bayer, J&J, GlaxoSmithKline, Portola, and Boehringer-Ingelheim. Dr Zotz has been a consultant for Sanofi-Aventis. Drs Monreal and FitzGerald have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Background: Acutely ill, hospitalized medical patients are at risk of VTE. Despite guidelines for VTE prevention, prophylaxis use in these patients is still poor, possibly because of fear of bleeding risk. We used data from the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) to assess in-hospital bleeding incidence and to identify risk factors at admission associated with in-hospital bleeding risk in acutely ill medical patients. Methods: IMPROVE is a multinational, observational study that enrolled 15,156 medical patients. The in-hospital bleeding incidence was estimated by Kaplan-Meier analysis. A multiple regression model analysis was performed to identify risk factors at admission associated with bleeding. Results: The cumulative incidence of major and nonmajor in-hospital bleeding within 14 days of admission was 3.2%. Active gastroduodenal ulcer (OR, 4.15; 95% CI, 2.21-7.77), prior bleeding (OR, 3.64; 95% CI, 2.21-5.99), and low platelet count (OR, 3.37; 95% CI, 1.84-6.18) were the strongest independent risk factors at admission for bleeding. Other bleeding risk factors were increased age, hepatic or renal failure, ICU stay, central venous catheter, rheumatic disease, cancer, and male sex. Using these bleeding risk factors, a risk score was developed to estimate bleeding risk. Conclusions: We assessed the incidence of major and clinically relevant bleeding in a large population of hospitalized medical patients and identified risk factors at admission associated with in-hospital bleeding. This information may assist physicians in deciding whether to use mechanical or pharmacologic VTE prophylaxis.
AB - Background: Acutely ill, hospitalized medical patients are at risk of VTE. Despite guidelines for VTE prevention, prophylaxis use in these patients is still poor, possibly because of fear of bleeding risk. We used data from the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) to assess in-hospital bleeding incidence and to identify risk factors at admission associated with in-hospital bleeding risk in acutely ill medical patients. Methods: IMPROVE is a multinational, observational study that enrolled 15,156 medical patients. The in-hospital bleeding incidence was estimated by Kaplan-Meier analysis. A multiple regression model analysis was performed to identify risk factors at admission associated with bleeding. Results: The cumulative incidence of major and nonmajor in-hospital bleeding within 14 days of admission was 3.2%. Active gastroduodenal ulcer (OR, 4.15; 95% CI, 2.21-7.77), prior bleeding (OR, 3.64; 95% CI, 2.21-5.99), and low platelet count (OR, 3.37; 95% CI, 1.84-6.18) were the strongest independent risk factors at admission for bleeding. Other bleeding risk factors were increased age, hepatic or renal failure, ICU stay, central venous catheter, rheumatic disease, cancer, and male sex. Using these bleeding risk factors, a risk score was developed to estimate bleeding risk. Conclusions: We assessed the incidence of major and clinically relevant bleeding in a large population of hospitalized medical patients and identified risk factors at admission associated with in-hospital bleeding. This information may assist physicians in deciding whether to use mechanical or pharmacologic VTE prophylaxis.
UR - https://www.scopus.com/pages/publications/78651416799
U2 - 10.1378/chest.09-3081
DO - 10.1378/chest.09-3081
M3 - Article
AN - SCOPUS:78651416799
SN - 0012-3692
VL - 139
SP - 69
EP - 79
JO - Chest
JF - Chest
IS - 1
ER -